Menu
← Oncology Approval Tracker
FDA DECISION ·
Blenrep
belantamab mafodotin-blmf · GlaxoSmithKline
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
With bortezomib and dexamethasone for adults with relapsed or refractory multiple myeloma after at least two prior lines that included a proteasome inhibitor and an immunomodulatory agent.
LAMPGEN ANALYSIS
Why it matters
The FDA approved a distinct BCMA-directed combination after withdrawal of the earlier single-agent indication.
What research teams should watch
Arrange REMS enrollment and timely eye examinations so corneal toxicity assessments inform each dosing decision.
PRIMARY RECORDS